cvdd: A subset of the 'framingham' teaching data

In riskCommunicator: G-Computation to Estimate Interpretable Epidemiological Effects

A subset of the framingham teaching data

Description

A subset of the framingham teaching dataset containing the following changes:

• removal of all observations where PERIOD == 2 or PERIOD == 3 (i.e. keep only PERIOD == 1)

• removal of all observations where PREVCHD == 1 (i.e. all patients with coronary heart disease at baseline)

• created a new variable, cvd_dth signifying an outcome of cardiovascular disease OR death (i.e. if the patient had either CVD or DEATH, this new variable is 1, otherwise 0)

• created a new variable, timeout, which calculates the number of days from the start of the study to cardiovascular disease, death, or loss to follow-up

• created a new variable, logpdays, which is the log of timeout

• created a new variable, nhosp, which is a simulated number of hospitalizations

Usage

data(cvdd)

Format

A data frame with 4240 rows and 31 variables:

RANDID

Unique identification number for each participant.

SEX

Participant sex. 0 = Male, 1 = Female.

TOTCHOL

Serum Total Cholesterol (mg/dL).

AGE

Age at exam (years).

SYSBP

Systolic Blood Pressure (mean of last two of three measurements) (mmHg).

DIABP

Diastolic Blood Pressure (mean of last two of three measurements) (mmHg).

CURSMOKE

Current cigarette smoking at exam. 0 = Not current smoker, 1 = Current smoker.

CIGPDAY

Number of cigarettes smoked each day. 0 = Not current smoker.

BMI

Body Mass Index, weight in kilograms/height meters squared.

DIABETES

Diabetic according to criteria of first exam treated or first exam with casual glucose of 200 mg/dL or more. 0 = Not a diabetic, 1 = Diabetic.

BPMEDS

Use of Anti-hypertensive medication at exam. 0 = Not currently used, 1 = Current use.

HEARTRTE

Heart rate (Ventricular rate) in beats/min.

GLUCOSE

Casual serum glucose (mg/dL).

educ

Level of completed education. 1 = 0-11 years, 2 = high school or GED, 3 = some college, 4 = college graduate or higher.

PREVSTRK

Prevalent Stroke. 0 = Free of disease, 1 = Prevalent disease.

PREVHYP

Prevalent Hypertensive. Subject was defined as hypertensive if treated or if second exam at which mean systolic was >=140 mmHg or mean Diastolic >=90 mmHg. 0 = Free of disease, 1 = Prevalent disease.

DEATH

Death from any cause. 0 = Did not occur during followup, 1 = Did occur during followup.

ANGINA

Angina Pectoris. 0 = Did not occur during followup, 1 = Did occur during followup.

HOSPMI

Hospitalized Myocardial Infarction. 0 = Did not occur during followup, 1 = Did occur during followup.

MI_FCHD

Hospitalized Myocardial Infarction or Fatal Coronary Heart Disease. 0 = Did not occur during followup, 1 = Did occur during followup.

ANYCHD

Angina Pectoris, Myocardial infarction (Hospitalized and silent or unrecognized), Coronary Insufficiency (Unstable Angina), or Fatal Coronary Heart Disease. 0 = Did not occur during followup, 1 = Did occur during followup.

STROKE

Atherothrombotic infarction, Cerebral Embolism, Intracerebral Hemorrhage, or Subarachnoid Hemorrhage or Fatal Cerebrovascular Disease. 0 = Did not occur during followup, 1 = Did occur during followup.

CVD

Myocardial infarction (Hospitalized and silent or unrecognized), Fatal Coronary Heart Disease, Atherothrombotic infarction, Cerebral Embolism, Intracerebral Hemorrhage, or Subarachnoid Hemorrhage or Fatal Cerebrovascular Disease. 0 = Did not occur during followup, 1 = Did occur during followup.

HYPERTEN

Hypertensive. Defined as the first exam treated for high blood pressure or second exam in which either Systolic is 6 140 mmHg or Diastolic 6 90mmHg. 0 = Did not occur during followup, 1 = Did occur during followup.

cvd_dth

Cardiovascular disease OR death. 0 = Did not occur during followup, 1 = Did occur during followup.

timeout

Number of days from the start of the study to cardiovascular disease, death, or loss to follow-up.

drop

Participant was lost to follow-up before 24 months complete followup. 0 = no, 1 = yes

glucoseyear6

Casual serum glucose (mg/dL) after 6 years of follow-up

logpdays

Natural log of timeout.

bmicat

BMI category. 0 = Normal, 1 = Underweight, 2 = Overweight, 3 = Obese.

nhosp

Simulated number of hospitalizations over 24 months, associated with age, sex, BMI, and diabetes (not collected in the Framingham study).

Details

The National Heart, Lung, and Blood Institute of the National Institutes of Health developed a longitudinal, epidemiology-focused dataset using the Framingham Heart Study. The Framingham Heart Study is a long term prospective study of the etiology of cardiovascular disease among a population of free living subjects in the community of Framingham, Massachusetts. The Framingham Heart Study was a landmark study in epidemiology in that it was the first prospective study of cardiovascular disease and identified the concept of risk factors and their joint effects. The study began in 1948 and 5,209 subjects were initially enrolled in the study. Participants have been examined biennially since the inception of the study and all subjects are continuously followed through regular surveillance for cardiovascular outcomes. Clinic examination data has included cardiovascular disease risk factors and markers of disease such as blood pressure, blood chemistry, lung function, smoking history, health behaviors, ECG tracings, Echocardiography, and medication use. Through regular surveillance of area hospitals, participant contact, and death certificates, the Framingham Heart Study reviews and adjudicates events for the occurrence of Angina Pectoris, Myocardial Infarction, Heart Failure, and Cerebrovascular disease. This dataset contains three clinic examinations and 20 year follow-up data on a large subset of the original Framingham cohort participants.

NOTE: This is a "teaching" dataset. Specific methods were employed to ensure an anonymous dataset that protects patient confidentiality; therefore, this dataset is inappropriate for publication purposes." The use of these data for the purposes of this package were approved on 11Mar2019 (request #7161) by NIH/NHLBI.

Source

https://biolincc.nhlbi.nih.gov/teaching/

riskCommunicator documentation built on June 1, 2022, 1:07 a.m.